Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775
Henk HJ, Deeter R, Kaye JA, Becker LK, Legg JC, Rothman KJ. Effect of age on neutropenia-related hospitalization in Non-Hodgkin's lymphoma patients receiving myelosuppressive chemotherapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):2082. doi: 10.1182/blood.V118.21.2082.2082
Kiladjian J, Al-Ali H, Gisslinger H, Knoops L, Waltzman RJ, Mendelson E, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):795. doi: 10.1182/blood.V118.21.795.795
Meyers JL, Yu YF, Davis KL. Medicare fee-for-service enrollees with acute myelogenous leukemia: an analysis of treatment patterns and patient survival. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):505. doi: 10.1182/blood.V118.21.505.505
Amend KL, Landon J, Thyagarajan (Hoffman) V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110
Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, Ziemiecki RM. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Jan; 118(21):97. doi: 10.1182/blood.V118.21.97.97
Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):2483. doi: 10.1182/blood.V114.22.2483.2483
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009 Jul;68(7):1177-83. doi: 10.1136/ard.2008.094904
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ. The development of the L-QoL: a quality of life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009 Feb;68(2):196-200. doi: 10.1136/ard.2007.086009
Herrinton LJ, Liu L, Shoor S, Mines D. Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Ann Rheum Dis. 2008 Apr;67(4):574-5. doi: 10.1136/ard.2007.075986
Mines D, Gu Y, Liu Q, Horne LN, Harrison MJ. Risk of active tuberculosis (TB) among biologic-naïve RA patients: retrospective cohort study in a US claims database. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):91.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Presented at the 2008 Annual European Congress of Rheumatology; June 2008. Paris, France. [abstract] Ann Rheum Dis. 2008; 67(Supplement II):51.
Nau DP, Steinke DT, Williams LK, Austin R, Lafata JE, Divine G, Pladevall-Vila M. Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007 Nov;41(11):1792-7.
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQol: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Ann Rheum Dis. 2007;66:640.
Mines D. Attributing treatment as a cause in individuals and populations. Presented at the 2006 Annual European Congress of Rheumatology; June 22, 2006. Amsterdam, The Netherlands. [abstract] Ann Rheum Dis. 2006; 65(Suppl 2):15.
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. The development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004 Feb 1;63(2):162-9.
Doward LC, Spoorenberg A, Whalley D, Cook SA, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003 Jan 1;62(1):20-6.
Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood. 2002 Jan 1;100(11):221A.
Fleming AD, Palka P, McDicken WN, Fenn LN, Sutherland GR. Verification of cardiac Doppler tissue images using grey-scale M-mode images. Ultrasound Med Biol. 1996 Jan 1;22(5):573-81. doi: 10.1016/0301-5629(95)02065-9
Fleming AD, McDicken WN, Sutherland GR, Hoskins PR. Assessment of colour Doppler tissue imaging using test-phantoms. Ultrasound Med Biol. 1994 Jan 1;20(9):937-51. doi: 10.1016/0301-5629(94)90053-1
Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993 Nov 1;82(9):2714-8.